Orexigen puts brakes on obesity program, blames 'unprecedented' CV demands from US FDA
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics' stock plunged as low as 34.3%, or $1.09, in morning trading on 3 June after the company said it was discontinuing development of its experimental weight-loss drug Contrave (naltrexone/bupropion), claiming the US FDA's demands for a preapproval cardiovascular outcomes trial are "unprecedented and would generate significantly more information than is necessary or feasible".